Related Experiment Video
Updated: Aug 6, 2025
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
291
[Methotrexate to prevent progression to rheumatoid arthritis?]
Alfons A den Broeder1,2, Noortje van Herwaarden1, Maike H M Wientjes1
1Sint Maartenskliniek, afd. Reumatologie, Nijmegen.
Nederlands Tijdschrift Voor Geneeskunde
|March 15, 2023
Summary
Methotrexate did not prevent Rheumatoid Arthritis progression from suspect arthralgia. However, methotrexate treatment did improve symptoms during and after use, offering valuable insights for managing early arthritis.
Area of Science:
- Rheumatology
- Clinical immunology
- Pharmacology
Context:
- Early arthritis management is crucial for long-term outcomes.
- Identifying predictors of Rheumatoid Arthritis (RA) development from arthralgia is an active research area.
- Methotrexate is a cornerstone therapy for established RA.
Purpose:
- To evaluate if early methotrexate intervention can prevent the transition from clinically suspect arthralgia to confirmed Rheumatoid Arthritis.
- To assess the impact of methotrexate on symptom severity in patients with suspect arthralgia.
Summary:
- The TREAT EARLIER study investigated methotrexate's efficacy in preventing Rheumatoid Arthritis onset in individuals with suspect arthralgia.
- The primary endpoint, prevention of RA evolution, was not met.
- Secondary analyses indicated significant symptom improvement during and following methotrexate treatment.
Impact:
- This study contributes to understanding the role of methotrexate in the very early stages of inflammatory arthritis.
- Findings necessitate careful interpretation regarding methotrexate's potential benefits beyond disease modification in suspect arthralgia.
- Highlights the need for further research into optimal treatment strategies for early inflammatory arthritis.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
221
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
221
01:21Rheumatic Heart Disease III: Medical Management
23
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
23
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
196
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
196
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
176
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
176
01:26Mitral Stenosis III: Medical Management
15
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
15
01:29Inflammatory Bowel Disease IV: Pharmacological Management
165
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
165